Atara Biotherapeutics Inc (ATRA) Institutional Ownership Tracker (Q2 2026)

ATRA ranks #7019 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ATRA is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

36 institutions disclose a position in ATRA, but none treat it as a major bet — even EcoR1 Capital, LLC, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

Steve Cohen has added to its ATRA position for two straight quarters, increasing it by $7.6M to reach $7.9M today.

Acadian Asset Management LLC has trimmed its ATRA position for two straight quarters, cutting it by $532.0K while still holding $444.0K.

ATRA is up 4.7% today, and institutions have been net buyers of $21.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ATRA reported a net loss of $16.7M over the trailing twelve months.

• Not yet profitable — net loss of $16.7M over the trailing twelve months
• Revenue declined 96.7% year over year
• Net income declined year over year, from $5.8M to -$16.7M
• Operating cash flow was negative, using $50.9M in cash
• Current ratio of 0.82x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)